Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact

FOR THE LATEST DEVELOPING NEWS

Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, January 6

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Sitemap

CytoDyn Inc. Sitemap

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2021 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap